Toxicity and Effects of Adjuvant Therapy in Colon Cancer: Results of the German Prospective, Controlled Randomized Multicenter Trial FOGT-1

Journal of Gastrointestinal Surgery

Volumn 5, Issue 3, 2001, Pages 275-281

  Staib, Ludger ^a   Link, Karl Heinz ^a   Beger, Hans Günther ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Adjuvant chemoimmunotherapy; Colon cancer; Effectiveness; FOGT 1 trial; Toxicity

Indexed keywords

ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL; FOLINIC ACID; IMMUNOLOGICAL ADJUVANT; LEVAMISOLE;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER STAGING; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; CLINICAL TRIAL; COLON RESECTION; COLON TUMOR; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; GERMANY; HUMAN; LEUKOPENIA; MORTALITY; MULTICENTER STUDY; NAUSEA; POSTOPERATIVE CARE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLECTOMY; COLONIC NEOPLASMS; DIARRHEA; FLUOROURACIL; GERMANY; HUMANS; INTERFERON ALFA-2A; LEUCOVORIN; LEUKOPENIA; LEVAMISOLE; NAUSEA; NEOPLASM STAGING; POSTOPERATIVE CARE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035350629     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(01)80048-2     Document Type: Article

References (43)

1. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-1450.
2. Windle R, Bell P, Shaw D. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 1987;74:569-572.
3. Moertel C, Fleming T, MacDonald J. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-358.
4. Köhne-Wömpner C, Schmoll H. Chemotherapeutic strategies in metastatic colorectal cancer: An overview of current clinical trials. Semin Oncol 1992;19:105-125.
5. Danenberg P, Lockshin A. Fluorinated pyrimidines as tight-binding inhibitors of thymidylate synthetase. Pharmacol Ther 1981;13:69-90.
6. Rustum Y, Trave F, Zakrzewski S. Biochemical and pharmacological basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr 1987;5:165-170.
7. Wadler S. The role of immunotherapy in colorectal cancer. Semin Oncol 1991;18(1 Suppl 1):27-38.
8. Nichols PH, Ward U, Ramsden CW, Primrose JN. The effect of 5-fluorouracil and alpha interferon and 5-fluorouracil and leucovorin on cellular anti-tumour immune responses in patients with advanced colorectal cancer. Br J Cancer 1994; 70:946-949.
9. Slaton J, Perrotte P, Inoue K, et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999;5:2726-2734.
10. Eigler F, Gabbert H, Herfarth C, et al. Interdisziplinäre Leitlinie zur Therapie des Kolonkarzinoms. Forum Dtsch Krebsgesellschaft 1999;14:132-138.
11. Hermanek P. Tumors of the gastrointestinal tract and the pancreas: Histopathology, staging and prognosis. Anticancer Res 1999;19:2393-2396.
12. Link K, Aigner K, Peschau K, et al. Concentration and time dependence of the toxicity of fluorinated pyrimidines to HT 29 colorectal carcinoma cells. Cancer Chemother Pharmacol 1988;22:58-62.
13. Machover D, Schwarzenberg L, Goldschmidt E, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: A pilot study. Cancer Treat Rep 1982;66:1803-1807.
14. Link KH, Staib L, Kreuser ED, Beger HG. Adjuvant treatment of colon and rectal cancer: Impact of chemotherapy, radiotherapy, and immunotherapy on routine postsurgical patient management. Forschungsgruppe Onkologie Gastrointestinaler Tumoren (FOGT). Recent Results Cancer Res 1996;142:311-352.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
16. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analysis. Biometrics 1994;50:1029-1041.
17. Moertel C, Fleming T, MacDonald J, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 1995;122: 321-326.
18. O'Connell M. Surgical Adjuvant Therapy of Colorectal Cancer. Dallas, Tex.: American Society of Clinical Oncology (Educational Book), 1994.
19. Hagmüller E, Lorenz D, Sturm J, et al. Long-term survival after surgical therapy of T4 colorectal carcinomas. Zentralbl Chir 1995;120:815-820.
20. Mamounas E, Rockette H, Jones J, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B vs. Dukes' C colon cancer: Results from four NSABP adjuvant studies (C-01, C-02, C-03, C-04). In Proceedings of the Thirty-Second Annual Meeting of the American Society of Clinical Oncology. Philadelphia, 1996, p 204.
21. Erlichman C, Marsoni S, Seitz J, et al. Event free and overall survival is increased by FUFA in resected B colon cancer: A pooled analysis of randomized trials. In Proceedings of the Thirty-Third Annual Meeting of the American Society of Clinical Oncology. Denver, 1997, p 280a.
22. Marsoni S. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer - International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939-944.
23. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer and bowel project protocol C-03. J Clin Oncol 1993;11:1879-1887.
24. Wadler S, Schwartz E, Goldmann L, et al. Fluorouracil and recombinant alpha-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;7:1769-1775.
25. Frasci G, Leone F, Monaco M, et al. 5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes' C colorectal cancer. Dis Colon Rectum 1994;37:643-650.
26. Prange H. Interferon-alpha - Zum Problem der persistierenden Neurotoxizität, Dtsch Ärztebl 1994;91(Heft 49):A3420-A3427.
27. Wolmark N, Bryant J, Smith R, et al. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 1998;90:1810-1816.
28. Staib L, Gutsche B, Link KH, Beger HG. Immune monitoring during adjuvant chemoimmunotherapy (in preparation).
29. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994;343: 1177-1183.
30. Riethmüller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16:1788-1794.
31. Weiss F. Withdrawal of Panorex (Edrecolomab) [letter]. Leiden, The Netherlands: Centocor BV, August 7, 2000.
32. Francini G, Petrioli R, Lorenzini L, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994;106:899-906.
33. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16:295-300.
34. Haller D, Catalano P, Macdonald J, Mayer R. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Five-year final report of INT-0089. In Proceedings of the Thirty-Fourth Annual Meeting of the American Society of Clinical Oncology. Los Angeles, 1998, p256a.
35. Wolmark N, Rockette H, Mamounas E, et al. The relative efficacy of 5-FU + leucovorin (FU-LV) 5-FU + levamisole (FU-LEV), and 5-FU + leukovorin + levamisole (FU-LV-LEV) in patients with Dukes' B and C carcinoma of the colon: First report of NSABP C-04. In Proceedings of the Thirty-Second Annual Meeting of the American Society of Clinical Oncology. Philadelphia, 1996, p 205.
36. Scheithauer W, Kornek GV, Marczell A, et al. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma. Br J Cancer 1998;77:1349-1354.
37. Zaniboni A, Labianca R, Marsoni S, et al. GIVIO-SITAC 01: A randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma - long term results and evaluation of the indicators of health-related quality of life. Gruppo Italiano Valutazione Interventi in Oncologia. Studio Italiano Terapia Adiuvante Colon. Cancer 1998;82: 2135-2144.
38. Johnston PG, Fisher ER, Rockette HE, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-2647.
39. Lenz HJ, Danenberg KD, Leichman CG, et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site. Clin Cancer Res 1998;4:1227-1234.
40. Kornmann M, Link KH, Lenz HJ et al. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 1997;118:29-35.
41. Fleischer K, Möller P, Link KH, Staib L. CEA in contrast to p53 is associated with response to adjuvant chemoimmunotherapy in colorectal cancer. In Encke A, Rothmund M, Hartel W, eds. Chirurgisches Forum 2000 für Experimentelle und Klinische Forschung. Berlin-Heidelberg-New York: Springer-Verlag, 2000, pp 1-5.
42. Hochtlen VW, Gruber R, Bodenmuller H, et al. Occult epithelial tumor cells detected in bone marrow by an enzyme immunoassay specific for cytokeratin 19. Int J Cancer 1997;70: 396-400.
43. Greenson JK, Isenhart CE, Rice R, et al. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 1994;73:563-569.